Bio‑Rad reported third‑quarter 2025 financial results, showing revenue of $653.0 million, a 0.5 % increase from $649.7 million in the same quarter last year.
The company posted a net loss of $341.9 million, largely due to a $398 million decline in the fair‑market value of its investment in Sartorius AG, compared with a $422.2 million gain in the prior year.
Non‑GAAP net income rose to $60.8 million, or $2.26 per diluted share, up from $56.3 million ($2.02) in Q3 2024. GAAP operating income was $65.3 million, while non‑GAAP operating income reached $77.0 million, reflecting disciplined cost management.
Revenue was $262 million from Life Science and $391 million from Clinical Diagnostics, with the latter segment experiencing margin compression due to higher material and labor costs, including increased expenses for diabetes testing reagents in China.
Management highlighted ongoing headwinds in academic research and biopharma markets, as well as lower reimbursement rates for diabetes testing in China, but emphasized continued focus on cost control, product mix optimization, and expansion of its Droplet Digital PCR platform.
The company reaffirmed its full‑year 2025 outlook, maintaining a currency‑neutral revenue growth range of 0 % to 1 % and a non‑GAAP operating margin target of 12 % to 13 %. Bio‑Rad also noted progress on its ddPCR strategy, including sales training for new platforms and the recent acquisition of Stilla Technologies to strengthen its portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.